Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

BACKGROUND: The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient to halt the disease progression. At the same time, pathological tau correlates...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Neurodegener
Hauptverfasser: Agadjanyan, Michael G., Zagorski, Karen, Petrushina, Irina, Davtyan, Hayk, Kazarian, Konstantin, Antonenko, Maxim, Davis, Joy, Bon, Charles, Blurton-Jones, Mathew, Cribbs, David H., Ghochikyan, Anahit
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2017
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5418694/
https://ncbi.nlm.nih.gov/pubmed/28472993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13024-017-0172-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge